COVID-19; Hemodialysis; Hybrid immunity; Systems immunology; mRNA vaccination; Molecular Medicine; Immunology and Microbiology (all); Veterinary (all); Public Health, Environmental and Occupational Health; Infectious Diseases
Abstract :
[en] [en] BACKGROUND: Clinical risk factors of deficient immune responses to COVID-19 mRNA vaccination in SARS-CoV-2 naive hemodialysis recipients (HDR) have already been identified. Clinical factors influencing hybrid immunity induced by SARS-CoV-2 infection and vaccination in HDR have not been reported.
METHODS: A comprehensive analysis of antibody (Ab) and T cell responses to two doses of BNT162b2 mRNA vaccination was performed in 103 HDR, including 75 SARS-CoV-2 naive and 28 experienced patients, and in 106 healthy controls (HC) not undergoing HD, including 40 SARS-CoV-2 naive and 66 experienced subjects. Clinical risk factors associated with lower humoral and cellular immunity were analyzed in SARS-CoV-2 naive and experienced HDR by univariate and multivariate analyses.
RESULTS: Naive HDR had lower neutralizing and non-neutralizing antibody responses to vaccination than naive HC; lower vaccine responses were correlated with previous transplantation, immunosuppressive treatment, corticosteroid treatment, hypoalbuminemia, older age, hypertension, and negative response to hepatitis B vaccination. In contrast, vaccine responses of SARS-CoV-2 experienced HDR were similar to those of HC and were correlated with time between infection and vaccination and with previous transplantation, but not with the other risk factors associated with lower vaccine responses in naive HDR.
CONCLUSION: COVID-19 vaccine responses are influenced by distinct risk factors in SARS-CoV-2 naive and experienced HDR. These observations have important implications for the understanding of vaccine-induced immunity and for the management of this vulnerable patient population.
Disciplines :
Immunology & infectious disease
Author, co-author :
Gemander, Nicolas; European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium, Department of Nephrology, Dialysis and Transplantation, Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium. Electronic address: nicolas.gemander@ulb.be
Kemlin, Delphine; European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium, Department of Nephrology, Dialysis and Transplantation, Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium
Depickère, Stéphanie; Platform for Interventional Studies, Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium
Kelkar, Natasha S; Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA
Sharma, Shilpee; European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium
Pannus, Pieter; European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium
Waegemans, Alexandra; European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium
Olislagers, Véronique; European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium
Dhondt, Emilie; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
Braga, Margarida; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
Heyndrickx, Leo; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
Michiels, Johan; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
Thiriard, Anaïs; European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium
Lemy, Anne; Department of Nephrology, Marie Curie Hospital, Charleroi, Belgium
Baudoux, Thomas; Department of Nephrology, Dialysis and Transplantation, Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium
Goossens, Maria E; Platform for Interventional Studies, Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium
Matagne, André ; Université de Liège - ULiège > Département des sciences de la vie > Enzymologie et repliement des protéines
Desombere, Isabelle; Laboratory of Immune Response, Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium
Ariën, Kevin K; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
Ackerman, Margaret E; Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA, Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
Le Moine, Alain; European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium, Department of Nephrology, Dialysis and Transplantation, Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium
Marchant, Arnaud; European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium
This study was co-funded by the Belgian Federal Government through Sciensano , Belgium, by the Fonds de la Recherche Scientifique, F.R.S.-FNRS, Belgium, and by the Fonds Erasme, Belgium. N.G. received a PhD studentship from the Fonds Erasme and from the F.R.S- FNRS. D.K. received a PhD studentship from the F.R.S- FNRS. A.M. is Research Director of the F.R.S.-FNRS. This study was supported in part by the US NIAID (grants R56AI165448 and P01AI162242 ).This study was co-funded by the Belgian Federal Government through Sciensano, Belgium, by the Fonds de la Recherche Scientifique, F.R.S.-FNRS, Belgium, and by the Fonds Erasme, Belgium. N.G. received a PhD studentship from the Fonds Erasme and from the F.R.S- FNRS. D.K. received a PhD studentship from the Fonds Erasme and from the F.R.S- FNRS. A.M. is Research Director of the F.R.S.-FNRS. This study was supported in part by the US NIAID (grants R56AI165448 and P01AI162242).
Jager, K.J., Kramer, A., Chesnaye, N.C., Couchoud, C., Sánchez-Álvarez, J.E., Garneata, L., et al. Results from the ERA-EDTA registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int 98 (2020), 1540–1548, 10.1016/j.kint.2020.09.006.
Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584 (2020), 430–436, 10.1038/s41586-020-2521-4.
Kemlin, D., Lemy, A., Pannus, P., Desombere, I., Gemander, N., Goossens, M.E., et al. Hybrid immunity to SARS-CoV-2 in kidney transplant recipients and hemodialysis patients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 22 (2022), 994–995, 10.1111/ajt.16853.
Rincon-Arevalo, H., Choi, M., Stefanski, A.-L., Halleck, F., Weber, U., Szelinski, F., et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol, 6, 2021, eabj1031, 10.1126/sciimmunol.abj1031.
Espi, M., Charmetant, X., Barba, T., Koppe, L., Pelletier, C., Kalbacher, E., et al. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int 100 (2021), 928–936, 10.1016/j.kint.2021.07.005.
Anand, S., Montez-Rath, M.E., Han, J., Garcia, P., Cadden, L., Hunsader, P., et al. SARS-CoV-2 vaccine antibody response and breakthrough infection in patients receiving Dialysis. Ann Intern Med 175 (2022), 371–378, 10.7326/M21-4176.
Stumpf, J., Siepmann, T., Lindner, T., Karger, C., Schwöbel, J., Anders, L., et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur, 9, 2021, 100178, 10.1016/j.lanepe.2021.100178.
Van Praet, J., Reynders, M., De Bacquer, D., Viaene, L., Schoutteten, M.K., Caluwé, R., et al. Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: a multicenter observational study. J Am Soc Nephrol JASN 32 (2021), 3208–3220, 10.1681/ASN.2021070908.
Broseta, J.J., Rodríguez-Espinosa, D., Rodríguez, N., Mosquera, M.D.M., Marcos, M.Á., Egri, N., et al. Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients. Am J Kidney Dis Off J Natl Kidney Found 78 (2021), 571–581, 10.1053/j.ajkd.2021.06.002.
Anand, S., Montez-Rath, M.E., Han, J., Garcia, P., Cadden, L., Hunsader, P., et al. Antibody response to COVID-19 vaccination in patients receiving Dialysis. J Am Soc Nephrol JASN 32 (2021), 2435–2438, 10.1681/ASN.2021050611.
Agur, T., Ben-Dor, N., Goldman, S., Lichtenberg, S., Herman-Edelstein, M., Yahav, D., et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospectivecohort study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc, 2021, gfab155, 10.1093/ndt/gfab155.
Affeldt, P., Koehler, F.C., Brensing, K.A., Gies, M., Platen, E., Adam, V., et al. Immune response to third and fourth COVID-19 vaccination in hemodialysis patients and kidney transplant recipients. Viruses, 14, 2022, 2646, 10.3390/v14122646.
Levin, M.J., Ustianowski, A., De Wit, S., Launay, O., Avila, M., Templeton, A., et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. N Engl J Med, 2022, NEJMoa2116620, 10.1056/NEJMoa2116620.
Huth, L., Schäfer, L., Almanzar, G., Lupoli, G., Bischof, M., Wratil, P.R., et al. Immunologic effect of bivalent mRNA booster in patients undergoing hemodialysis. N Engl J Med, 2023, NEJMc2216309, 10.1056/NEJMc2216309.
Udomkarnjananun, S., Takkavatakarn, K., Praditpornsilpa, K., Nader, C., Eiam-Ong, S., Jaber, B.L., et al. Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis. J Nephrol 33 (2020), 343–354, 10.1007/s40620-019-00668-1.
Kong, N.C.T., Beran, J., Kee, S.A., Miguel, J.L., Sánchez, C., Bayas, J.-M., et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 73 (2008), 856–862, 10.1038/sj.ki.5002725.
Chaves, S.S., Daniels, D., Cooper, B.W., Malo-Schlegel, S., Macarthur, S., Robbins, K.C., et al. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine 29 (2011), 9618–9623, 10.1016/j.vaccine.2011.10.057.
Attias, P., Sakhi, H., Rieu, P., Soorkia, A., Assayag, D., Bouhroum, S., et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int 99 (2021), 1490–1492, 10.1016/j.kint.2021.04.009.
Goossens, M.E., Neven, K.Y., Pannus, P., Barbezange, C., Thomas, I., Gucht, S.V., et al. The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff - study protocol description and presentation of preliminary findings on symptoms. Arch Public Health Arch Belg Sante Publique, 79, 2021, 195, 10.1186/s13690-021-00715-z.
Gemander, N., Kemlin, D., Depickère, S., Kelkar, N.S., Pannus, P., Sharma, S., et al. Hybrid immunity overcomes defective immune response to COVID-19 vaccination in kidney transplant recipients. Kidney Int Rep, 0, 2023, 10.1016/j.ekir.2023.12.008.
Tomasi, L., Thiriard, A., Heyndrickx, L., Georges, D., Van den Wijngaert, S., Olislagers, V., et al. Younger children develop higher effector antibody responses to SARS-CoV-2 infection. Open forum. Infect Dis Ther, 9, 2022, ofac554, 10.1093/ofid/ofac554.
Mariën, J., Ceulemans, A., Michiels, J., Heyndrickx, L., Kerkhof, K., Foque, N., et al. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. J Virol Methods, 288, 2021, 114025, 10.1016/j.jviromet.2020.114025.
Brown, E.P., Licht, A.F., Dugast, A.-S., Choi, I., Bailey-Kellogg, C., Alter, G., et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods 386 (2012), 117–123, 10.1016/j.jim.2012.09.007.
Brown, E.P., Dowell, K.G., Boesch, A.W., Normandin, E., Mahan, A.E., Chu, T., et al. Multiplexed fc array for evaluation of antigen-specific antibody effector profiles. J Immunol Methods 443 (2017), 33–44, 10.1016/j.jim.2017.01.010.
Fischinger, S., Fallon, J.K., Michell, A.R., Broge, T., Suscovich, T.J., Streeck, H., et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J Immunol Methods, 473, 2019, 112630, 10.1016/j.jim.2019.07.002.
Ackerman, M.E., Moldt, B., Wyatt, R.T., Dugast, A.-S., McAndrew, E., Tsoukas, S., et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366 (2011), 8–19, 10.1016/j.jim.2010.12.016.
Torres, I., Albert, E., Giménez, E., Alcaraz, M.J., Botija, P., Amat, P., et al. B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents. Clin Microbiol Infect 27 (2021), 1672–1677, 10.1016/j.cmi.2021.06.013.
Giménez, E., Albert, E., Torres, I., Remigia, M.J., Alcaraz, M.J., Galindo, M.J., et al. SARS-CoV-2-reactive interferon-γ-producing CD8+ T cells in patients hospitalized with coronavirus disease 2019. J Med Virol 93 (2021), 375–382, 10.1002/jmv.26213.
R Core Team, R: A language and environment for statistical computing. R foundation for statistical computing. Vienna, Austria. 2013.
Wickham, H., ggplot2: Elegant graphics for data analysis. 2016, Springer-Verlag, New York.
Grupper, A., Sharon, N., Finn, T., Cohen, R., Israel, M., Agbaria, A., et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol CJASN 16 (2021), 1037–1042, 10.2215/CJN.03500321.
Jolliffe, I.T., Cadima, J., Principal component analysis: a review and recent developments. Philos Transact A Math Phys Eng Sci, 374, 2016, 20150202, 10.1098/rsta.2015.0202.
Anft, M., Blazquez-Navarro, A., Paniskaki, K., Skrzypczyk, S., Appel, H., Pfab, T., et al. SARS-CoV-2-reactive cellular and humoral immunity in hemodialysis population. Kidney Int 99 (2021), 1489–1490, 10.1016/j.kint.2021.03.032.
Laidlaw, B.J., Ellebedy, A.H., The germinal Centre B cell response to SARS-CoV-2. Nat Rev Immunol 22 (2022), 7–18, 10.1038/s41577-021-00657-1.
Woodruff, M.C., Ramonell, R.P., Nguyen, D.C., Cashman, K.S., Saini, A.S., Haddad, N.S., et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol 21 (2020), 1506–1516, 10.1038/s41590-020-00814-z.
De Vriese, A.S., Reynders, M., IgG antibody response to SARS-CoV-2 infection and viral RNA persistence in patients on maintenance hemodialysis. Am J Kidney Dis Off J Natl Kidney Found 76 (2020), 440–441, 10.1053/j.ajkd.2020.05.009.
Dudreuilh, C., Kumar, N., Moxham, V., Hemsley, C., Goldenberg, S., Moutzouris, D.-A., De-isolation of COVID-19–positive hemodialysis patients in the outpatient setting: a single-center experience. Kidney Int 98 (2020), 236–237, 10.1016/j.kint.2020.04.021.
Alfano, G., Morisi, N., Ferri, C., Fontana, F., Giovanella, S., Ligabue, G., et al. Prolonged RT-PCR test positivity in hemodialysis patients with COVID-19. Ren Replace Ther, 9, 2023, 35, 10.1186/s41100-023-00487-y.
De Vriese, A.S., Van Praet, J., Reynders, M., Heylen, L., Viaene, L., Caluwé, R., et al. Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in haemodialysis patients. Clin Kidney J 14 (2021), 2446–2448, 10.1093/ckj/sfab147.
Banham, G.D., Godlee, A., Faustini, S.E., Cunningham, A.F., Richter, A., Harper, L., et al. Hemodialysis patients make long-lived antibodies against SARS-CoV-2 that may be associated with reduced reinfection. J Am Soc Nephrol JASN 32 (2021), 2140–2142, 10.1681/ASN.2021020188.
Muir, L., Jaffer, A., Rees-Spear, C., Gopalan, V., Chang, F.Y., Fernando, R., et al. Neutralizing antibody responses after SARS-CoV-2 infection in end-stage kidney disease and protection against reinfection. Kidney Int Rep 6 (2021), 1799–1809, 10.1016/j.ekir.2021.03.902.
Danthu, C., Hantz, S., Dahlem, A., Duval, M., Ba, B., Guibbert, M., et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol JASN 32 (2021), 2153–2158, 10.1681/ASN.2021040490.
Gao, F., Mallajoysula, V., Arunachalam, P.S., van der Ploeg, K., Manohar, M., Röltgen, K., et al. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection. Immunity 56 (2023), 864–878.e4, 10.1016/j.immuni.2023.03.005.
Painter, M.M., Mathew, D., Goel, R.R., Apostolidis, S.A., Pattekar, A., Kuthuru, O., et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity 54 (2021), 2133–2142.e3, 10.1016/j.immuni.2021.08.001.
Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol, 6, 2021, eabi6950, 10.1126/sciimmunol.abi6950.
Reynolds, C.J., Pade, C., Gibbons, J.M., Butler, D.K., Otter, A.D., Menacho, K., et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science 372 (2021), 1418–1423, 10.1126/science.abh1282.
Xie, C., Yao, R., Xia, X., The advances of adjuvants in mRNA vaccines. NPJ Vaccines, 8, 2023, 162, 10.1038/s41541-023-00760-5.
Bates, T.A., Leier, H.C., McBride, S.K., Schoen, D., Lyski, Z.L., Lee, D.X., et al. An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants. JCI Insight, 8, 2023, e165265, 10.1172/jci.insight.165265.
Arunachalam, P.S., Scott, M.K.D., Hagan, T., Li, C., Feng, Y., Wimmers, F., et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596 (2021), 410–416, 10.1038/s41586-021-03791-x.
